TXNIP knockdown by small interfering RNA can overcome the diabetes-related pathologies of angiogenesis, cardiomyopathy, and renal injury, and alleviates the apoptosis and inflammation of retinal cells in diabetic mice [68], which indicates that TXNIP could act as a therapeutic target. This evidence concerns the gene TXNIP and cardiomyopathy.